What is the preferred vaccine for preventing herpes zoster and its complications in immunocompetent adults?

The preferred vaccine for preventing herpes zoster and its complications in immunocompetent adults is the recombinant, adjuvanted zoster vaccine. This vaccine, known as Shingrix, is specifically designed to provide a stronger immune response against the varicella-zoster virus, which causes both chickenpox and herpes zoster (shingles).

One of the key advantages of the recombinant, adjuvanted vaccine is its non-live formulation, making it safe for a wider range of individuals, including those who are immunocompromised. Clinical trials have demonstrated that this vaccine is more effective than the live attenuated zoster vaccine, particularly in older adults, who are at a higher risk for complications from shingles.

Additionally, the adjuvant included in the recombinant vaccine enhances the immune response, leading to greater efficacy and durability in protection compared to previous vaccines. This makes it the recommended option for preventing herpes zoster in immunocompetent adults and helps to significantly reduce the incidence and severity of associated complications, such as postherpetic neuralgia. Overall, its effectiveness and safety profile support its status as the preferred vaccine for this purpose.